OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
Rhea-AI Summary
OKYO Pharma (Nasdaq: OKYO) filed its Annual Report on Form 20-F for the year ended March 31, 2026, and reported a strengthened cash position supporting its late-stage development plans. According to the company, it raised approximately $25 million during the fiscal year, including a February 2026 public offering generating about $22 million in gross proceeds.
OKYO reported cash and cash equivalents of roughly $20.6 million at March 31, 2026, which it expects will fully fund the FDA-agreed global Phase 3 NEPTUNE pivotal trial of urcosimod in neuropathic corneal pain. NEPTUNE, planned to start in the second half of 2026, will enroll about 111 patients in the US and Europe, randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen and is designed as a potential registrational study following positive FDA Type D feedback.
Positive
- $25 million total capital raised during fiscal year ended March 31, 2026
- February 2026 public offering generated about $22 million in gross proceeds
- Cash and cash equivalents of approximately $20.6 million at March 31, 2026
- Company expects to be fully funded through completion of Phase 3 NEPTUNE trial
- FDA-agreed global Phase 3 NEPTUNE design with potential single-trial approval pathway
- NEPTUNE trial to enroll about 111 patients with 2:1 urcosimod-to-placebo randomization
Negative
- None.
News Market Reaction – OKYO
In the Jul 20 session, OKYO declined 4.20%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.1x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 08 | Phase 3 FDA feedback | Positive | -5.1% | Positive FDA Type D feedback supported NEPTUNE Phase 3 design and registration pathway. |
| Mar 18 | Phase 2 quality data | Positive | +1.3% | Phase 2a quality-of-life improvements exceeded placebo across several patient-reported domains. |
| Jan 30 | Phase 2 presentation | Positive | +0.5% | Phase 2 urcosimod results were accepted for presentation at the ASCRS Annual Meeting. |
| Dec 11 | Phase 2 nerve outcomes | Positive | +6.9% | Exploratory corneal nerve imaging showed directionally favorable structural outcomes. |
| Sep 22 | Registration pathway trial | Positive | +13.6% | Company announced a 100-patient trial following reported Phase 2 pain-reduction results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial announcements aligned positively in four of five tag-specific events, while the latest FDA-related update diverged with a negative reaction.
Key Terms
form 20-f regulatory
phase 3 pivotal trial medical
g-protein-coupled-receptor technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SEC’s website and the Company’s investor relations page. In conjunction with the filing, the Company provided a positive corporate update on its financial strength and clinical momentum.
“We are pleased to announce the filing of our annual report, which reflects substantial progress across our operations,” said Keeren Shah, Chief Financial Officer of OKYO Pharma. “During the year we raised approximately
Recent Capital Raise Backed by Renowned Investment Funds
OKYO Pharma successfully completed a public offering in February 2026 raising approximately
Robust Cash Position Enables Completion of Phase 3 Pivotal Trial
The strengthened financial position, with cash and cash equivalents of approximately
Overview of the NEPTUNE Clinical Trial
OKYO is advancing the NEPTUNE trial (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global Phase 3 pivotal study planned for initiation in the second half of 2026. The trial will enroll approximately 111 patients in the US and Europe, randomized 2:1 to receive
About Urcosimod
OKYO’s lead candidate, urcosimod, is a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled-receptor which is typically found on immune cells of the eye responsible for the ocular inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has demonstrated ocular analgesic and anti-inflammatory pharmacologic activity through its dual mechanism of action, supporting its therapeutic potential to address the significant unmet medical need for patients with neuropathic corneal pain.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2026. The company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements, except as may be required by law.
For further information, please visit www.okyopharma.com.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com
